Last Updated on September 6, 2024 by The Health Master
Supreme Court
In a significant blow to the unregulated advertising of Ayurvedic, Siddha, and Unani medicines, the Supreme Court stayed a notification issued by the Ministry of Ayush.
This notification aimed to remove rule 170 of the Drugs and Cosmetics Rules, 1945, which prohibits misleading advertisements of these traditional medicines.
Background
The Supreme Court’s decision comes in response to a May 2024 order that directed advertisers to submit a self-declaration before issuing any advertisement related to Ayurvedic, Siddha, or Unani products.
This declaration was akin to the guidelines for cable television networks, ensuring transparency and accountability.
Ministry of Ayush’s Attempt to Omit Rule 170
Despite the court’s clear directives, the Ministry of Ayush issued a notification in July 2024, seeking to remove rule 170.
This move directly contradicted the Supreme Court’s earlier order and raised concerns about the government’s commitment to protecting public health.
Supreme Court’s Intervention
The Supreme Court, recognizing the potential harm caused by misleading advertisements, swiftly intervened.
The bench of Justices Hima Kohli and Sandeep Mehta stayed the notification, effectively preventing its implementation.
The court emphasized that the notification violated the spirit of its May 2024 order.
Government’s Response and Next Steps
The Centre, represented by Additional Solicitor General K M Nataraj, indicated its intention to file an affidavit clarifying its position on the matter.
This suggests that the government may be reconsidering its approach to regulating Ayurvedic, Siddha, and Unani advertising.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Ayush ministry prohibits misleading Advertisement
Court imposes Rs. 90,000 fine on 4 Pharma Units for misleading Ads
Drug recall: Aurobindo, Glenmark, FDC recall drugs due to Quality Issues
CDSCO must maintain a registry of all Brand Name of Drugs: Dr BR Jagashetty
Jan Aushadhi: A Lifeline for Affordable Healthcare in India
Pharma Industry seeks more time to implement Revised Schedule M
Govt notifies Delhi Drug Inspector Recruitment Rules
156 Drugs banned in India: Download list
Drug alert: 70 drug samples declared as NSQ in July 2024
USFDA approval granted for Glycopyrrolate Oral Solution
Deadly Fire Ravages Pharma Company in Andhra Pradesh
USFDA inspection with positive VAI to Strides Pharma at Chennai
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
